FibroScan® expert 630 by echosens

The complete non-invasive solution for advanced liver disease assessment

FibroScan® expert 630 by echosens

The complete non-invasive solution for advanced liver disease management

Expand clinical capabilities with spleen stiffness measurement and ultrasound localization system.
Enhance exam efficiency with improved ergonomics and high-speed processing.

Powered by
LSM* by VCTE™
Liver Fibrosis
LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment.
- It is the standard for non-invasive evaluation of liver stiffness.[1]
- 3,300+ peer-reviewed publications support the use of LSM by VCTE™.

CAP™
Liver Steatosis
CAP™ is unique, patented and validated for liver steatosis assessment.
- 900 international and peer-reviewed articles support the use of CAP™.[2,3]

SSM* by VCTE™
Portal hypertension
SSM by VCTE™ is unique, patented and validated for portal hypertension assessment and can be used for risk stratification of patients with advanced CLD.[4]
- It is a new marker for non-invasive evaluation of spleen stiffness.
- 110+ peer-reviewed publications support the use of SSM by VCTE™

The new Baveno VII guidelines confirm the value of using FibroScan® for the management of patients with advanced chronic hepatitis, include the measurement of spleen stiffness (SSM by VCTE™), with the first associated diagnostic thresholds.

What makes FibroScan® unique?

Fast
A painless exam performed in less than 10 minutes to provide immediate results at the point-of-care.

Intuitive
Can be performed by any trained operator (physician, nurse).

Best in Class
The non-invasive gold standard solution validated by 3,300+ peer-reviewed publications and 160 international guidelines.

Reliable
Standardized examination with exceptional precision and reproducibility that can be utilized in 99% of patients.[2,3]

Original
Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.

When evidence matters and consistency counts
- Pioneer in the field of liver elastography
- FibroScan® produces biomarkers that can assess and monitor patients over time
- FibroScan® uses uniform algorithms that minimize inter-operator variability and eliminate inter-system variability
- 7,000+ FibroScan® installed worldwide enabling millions of liver examinations
- Winner of the Red Dot Design Award (FibroScan® 430 Mini+ model)

FibroScan® related solutions

FibroScan® gateway by echosens

Optimize clinical workflows with real-time secure data transmission

Save time, secure data, and improve patient follow-up with FibroScan® Gateway. FibroScan® Gateway acts as an integration engine, automatically uploading and storing examinations to the EHR (Electronic Health Record).

Scores by echosens

Enhancing FibroScan® liver disease assessment with biological markers

Fast*	Agile 3+	Agile 4
Identification of at-risk NASH patients	Identification of advanced fibrosis in NAFLD patients	Identification of cirrhosis in NAFLD patients

Your everyday FibroScan® companion

Assess your patient's liver health in just a few clicks

MyFibroScan

Available on myfibroscan.com or on the myFibroScan app

Available on the App Store | ANDROID APP ON Google play

FibroScan® by echosens

The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan® is right for you?

		FibroScan® mini+	FibroScan® mini+	FibroScan® compact	FibroScan® expert
Capabilities	LSM by VCTE™	✓	✓	✓	✓
	CAP™*		✓	✓	✓
	SSM by VCTE™				✓
Features	FibroScan® Gateway compatibility	✓	✓	✓	✓
	MyFibroScan® compatibility	✓	✓	✓	✓
	Embedded ultrasound localization system for assessment of obese or complex patients				✓
	High-speed processing				✓
	Integrated barcode reader				✓
Ergonomics	Versatile and adaptive design: from transportable to cart-based device with dedicated roll stand			✓	
	Fully transportable	✓	✓		
	Battery-powered	✓	✓	✓	
	Weight	5 kg	5 kg	10 kg	46 kg

*Additional cost

because liver health matters

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022
3. Razo S, Cifuentes C, Mezlez J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2012;25(8):905-911. doi:10.1097/MEG.0b013e32835fc0d
4. Stefanescu H, Marasco G, Calès P, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-183. doi:10.1111/liv.14228